{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:31:10Z","timestamp":1790249470817,"version":"4.1.0"},"reference-count":10,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Res"],"published-print":{"date-parts":[[2011]]},"abstract":"<jats:p>&lt;i&gt;Objective:&lt;\/i&gt; To examine the effect of recombinant canstatin protein on the corneal neovascularization (CorNV) in an alkaline burn-induced CorNV model. &lt;i&gt;Methods:&lt;\/i&gt; This study involved 50 C57BL\/6 mice. CorNV was induced by an alkaline burn of the corneas with 1 &lt;i&gt;N&lt;\/i&gt; NaOH under general anesthesia. Beginning 24 h after CorNV induction, recombinant canstatin protein was administered intraperitoneally at 5 or 10 mg\/kg body weight once a day for up to 14 days. CorNV was evaluated by slit-lamp microscopy. Growth factors and cytokines relating to neovascularization and inflammation in the corneas were evaluated by real-time polymerase chain reaction (RT-PCR), Western blotting, immunohistochemistry or ELISA. &lt;i&gt;Results:&lt;\/i&gt; Recombinant canstatin protein significantly inhibited CorNV. Compared to the untreated or PBS-treated CorNV group, expression of vascular endothelial growth factor (VEGF) markedly decreased in the canstatin-treated group as detected by various methods. Western blotting and RT-PCR showed that the canstatin treatment inhibited the expression of hypoxia-inducible factor and VEGF. Day 7 revealed the greatest changes: ELISA assay showed that TNF-\u03b1 also significantly decreased in canstatin-treated corneas. &lt;i&gt;Conclusions:&lt;\/i&gt; Recombinant canstatin protein suppressed experimental CorNV, suggesting that canstatin may serve as a useful angiogenic inhibitor for the treatment of neovascularization-related corneal diseases.<\/jats:p>","DOI":"10.1159\/000322804","type":"journal-article","created":{"date-parts":[[2011,1,17]],"date-time":"2011-01-17T07:56:57Z","timestamp":1295251017000},"page":"66-72","source":"Crossref","is-referenced-by-count":13,"title":["Inhibitory Effect of Canstatin in Alkali Burn-Induced Corneal Neovascularization"],"prefix":"10.1159","volume":"46","author":[{"given":"Ye","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2011,1,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097%2F00003226-198706040-00004"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038%2F386671a0"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3109%2F10409239209082560"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1167%2Fiovs.04-0753"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1074%2Fjbc.275.2.1209"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038%2F359843a0"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1167%2Fiovs.04-1172"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1582-4934.2008.00415.x"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1167%2Fiovs.09-4571"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.ophtha.2009.04.016"}],"container-title":["Ophthalmic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/322804","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/322804","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/322804","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T19:14:52Z","timestamp":1745435692000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000322804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":10,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2011,7,1]]},"published-print":{"date-parts":[[2011,7,25]]}},"URL":"https:\/\/doi.org\/10.1159\/000322804","archive":["Portico"],"relation":{},"ISSN":["0030-3747","1423-0259"],"issn-type":[{"value":"0030-3747","type":"print"},{"value":"1423-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}